Current studentsExisting staffContact us
 

A case-control study investigating the association of TP53 rs1042522 and CDH1 rs16260 polymorphisms with prostate cancer risk

Simple item page
dc.contributor.authorAkter, R.
dc.contributor.authorIslam, M.S.
dc.contributor.authorIslam, M.S.
dc.contributor.authorAziz, M.A.
dc.contributor.authorHussain, M.S.
dc.contributor.authorMillat, M.S.
dc.contributor.authorUddin, M.S.
dc.contributor.authorIslam, M.S.
dc.date.issued2021
dc.description.abstractObjectives: Prostate cancer is the most frequent non-cutaneous malignancy in men. Numerous genetic factors play a crucial role in the progression of prostate cancer. This study was undertaken to reveal the correlation of TP53 rs1042522 and CDH1 rs16260 polymorphisms with the risk of prostate cancer in the Bangladeshi population. Materials and methods: We recruited 210 prostate cancer patients and 210 healthy controls for the investigation. Genotyping was conducted using the PCR-RFLP technique. Results: In case of TP53 gene rs1042522, the association analysis revealed that all genetic models were linked with significantly increased risk for prostate cancer development (CG vs. CC: OR = 1.99, p = 0.001; GG vs. CC: OR = 4.82, p < 0.00; CG vs. CC + GG: OR = 1.52, p = 0.041; CG + GG vs. CC: OR = 2.44, p < 0.00; GG vs. CC + CG: OR = 3.64, p = 0.00; G vs. C: OR = 2.32, p < 0.00). Again, the second variant rs16260 in CDH1 gene also showed significantly enhanced association in all genetic models for the development of prostate cancer (CA vs. CC: OR = 2.20, p < 0.00; AA vs. CC: OR = 2.77, p = 0.012; CA vs. CC + AA: OR = 1.98, p = 0.001; CA + AA vs. CC: OR = 2.29, p = 0.00; A vs. C: OR = 1.99, p < 0.00) except the AA vs. CC + CA model. Conclusions: Our study indicates a significant association of TP53 rs1042522 and CDH1 rs16260 polymorphisms with increased prostate cancer risk in the Bangladeshi population. However, replication studies are required in different populations to validate our findings.
dc.identifier.citationMeta Gene, 2021; 30(100962):1-6
dc.identifier.doi10.1016/j.mgene.2021.100962
dc.identifier.issn2214-5400
dc.identifier.urihttps://hdl.handle.net/11541.2/31741
dc.language.isoen
dc.publisherElsevier
dc.rightsCopyright 2021 Elsevier
dc.source.urihttps://doi.org/10.1016/j.mgene.2021.100962
dc.titleA case-control study investigating the association of TP53 rs1042522 and CDH1 rs16260 polymorphisms with prostate cancer risk
dc.typeJournal article
pubs.publication-statusPublished
ror.mmsid9916697224701831

Files

Collections